- A multi-disciplinary, collaborative alliance of University of Washington health sciences research groups focused on comparative effectiveness research, technology assessment, and health system evaluation
- Community of engaged peers, research teams and like-minded collaborators
- Builds upon existing and available resources and creates economies of scale for high-impact research
Join the CHASE Alliance Listserv!
- The CHASE Alliance was formed in November 2009 to bring together successful and respected UW research groups and community partners under an umbrella with a common mission to elevate multi-disciplinary, high impact comparative and systems effectiveness research and implementation. We currently have over 100 members on our listserv who are interested in staying in touch about current research, news and development in related fields.
- You may enroll in our listserv here
- You may send news and announcements through to listserv members by emailing your post here
- A special CHASE listserv has been set up to facilitate PCORI specific discussion. Register for this Listserv here
News & Events
- June 23 2014
- Guest Speaker: William Hollingsworth, PhD, MSc, University of Bristol
- The CHASE Alliance, Comparative Effectiveness, Cost & Outcomes Research Center (CECORC) and the Pharmaceutical Outcomes Research & Policy Program (PORPP) are please to present a special session with William Hollingworth, PhD, MSc, Professor of Health Economics, University of Bristol.
This special session will be held on 6/23/2014, at 3pm, in H371 of the Health Science Building.
Dr. Hollingworth is a noted health economist whose applied research focuses on measuring cost-effectiveness of healthcare interventions in randomized controlled trials and using decision analysis models. His work includes the economic evaluation of diagnostic tests and interventions for low back pain and sciatica, and has also collaborated widely with colleagues with interests in other clinical topics including cancer care, public health prevention, mental health and child health. His methodological research interests center on the use of variations in clinical practice as a method for commissioners and clinicians to identify and prioritize opportunities for disinvestment in healthcare.
Please join us for this special session.
Adobe Connect instructions:
Go to http://confer.uw.edu/deptpharm .
Login as a guest. Type your name into the field and click Enter Room.
Click the Request Entry button.
To join the call, dial 1-800-379-6841
Participant Code: 394654
- May 07 2014
- Harborview Injury Prevention and Research Center Names New Director
- Stakeholders in the University of Washington School of Medicine, School of Public Health, School of Nursing, School of Social Work and UW Medicine selected Monica S. Vavilala, MD director for HIPRC effective April 1, 2014.
Dr. Vavilala is Professor of Anesthesiology and Pediatrics and Adjunct Professor of Neurological Surgery and Radiology at the University of Washington. She received her undergraduate education from the University of Houston and her medical degree from University of Texas Medical School in Houston, Texas. She completed two residencies, her first in pediatrics at the University of Texas Medical School and the second in anesthesiology at the University of Washington. Dr. Vavilala is an expert in the care of injured patients, has authored over 150 peer reviewed publications related to injury, and is internationally known for her work in traumatic brain injury. As a 20 year faculty member in the UW School of Medicine, she has mentored over 27 fellows across UW, has current research support from the National Institute of Neurological Disease and Stroke, and is the co-director of the NICHD sponsored UW Pediatric Injury Training Program.
Dr. Vavilala is the first anesthesiologist in the nation to lead an injury research center and the only anesthesiologist on the Brain Trauma Foundation Guidelines working group pertaining to the acute care management of patients with severe traumatic brain injury. “Dr. Vavilala brings to the Center the energy and commitment to move it ahead and keep it at the forefront of injury research and prevention,” said Dr. Frederick P. Rivara, UW Professor of Pediatrics and founder of the Center.
- May 06 2014
- Guest Speaker: Dr. Teh-Wei Hu - University of California, Berkeley
- Speaker: Distinguished Professor Teh-Wei Hu of the University of California, Berkeley
Topic: "Recent Health Care Reform In China: The Role of Government”
Location: Room SCC 303
Time: 11:30 A.M.- 12:30 P.M.
- June 02 2014
- CHASE WIP | UW Health Science Building | 3:45 - 5:00 P.M.
- Speaker: Benjamin Wilfond, MD, Director, Truman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute; Professor, UW Department of Pediatrics
Location: Health Science Building, H371
Time: 3:45-5:00 P.M.
- May 29 2014
- PHEnOM Seminar | UW Tower | 3:00-4:30 P.M.
- Speaker: Andrew J. Brunskill
Departments of Epidemiology and Health Services, University of Washington
Topic: What is Different about Smoking in Pregnancy : Psychology, Physiology and Economics
Location: UW Tower, 4333 Brooklyn Ave NE, 22nd floor Boardroom
Time: 3:00-4:30 P.M.
- May 19 2014
- CHASE WIP | UW Health Science Building | 3:00-4:30 P.M.
- Speaker: Sean Rundell, PhD, Senior Fellow, UW Department of Radiology
Topic: The relationship between knee or hip osteoarthritis and back outcomes over 1 year among older adults with new visits for back pain
Location: UW Health Science Building, H371
Time: 3:00-4:30 P.M.
The Digestive Disease Center (DDC) and Inflammatory Bowel Disease Research
Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) are common and vexing problems. The causes and triggers for these conditions remain unclear, and consistently effective treatment continues to be elusive. Ulcerative colitis and Crohn’s disease are two types of chronic inflammation affecting the gastrointestinal tract, and sometimes their symptoms and other features overlap. Familial clustering and genetic factors also appear to be involved
Patients affected with these diseases often undergo a long course of intermittent relapses and remissions, greatly diminishing their quality of life. In most cases, patients are required to take long-term medications to keep a potential relapse in check. Bleeding and stricture formation leading to obstruction and perforation are complications of the continuous inflammatory process. In some cases, repeated operations are required to treat complications. Patients with ulcerative colitis may eventually face removal of the colon, which usually cures the disease but may create other significant health issues. However, for patients with Crohn’s disease, which can affect any segment of the gastrointestinal tract, surgery is seldom curative. In both cases, chronic inflammation can lead to the development of cancer.
UW Medicine investigators are among the vanguard of those conducting new clinical trials using biological agents (not traditional immunosuppressants) for the treatment of chronic inflammatory bowel disease during relapse. There are substantial numbers of sufferers of chronic inflammatory bowel diseases in the Pacific Northwest, yet there is no organized and concerted effort to push research forward, educate patients and the public, and coordinate effective treatment and clinical trials in a single research center. The Division of Gastroenterology at UW Medicine is equipped to meet the challenge, taking responsibility for leading a multi-disciplinary approach to research in chronic inflammatory bowel disease in the Pacific Northwest, and contributing to the national effort to advance research and treatment. At UW Medicine, researchers are planning to create a database of patients suffering from chronic inflammatory bowel diseases and attempt to match the risk factors and the clinical features with detailed and serial DNA micro-array analysis. Researchers also plan to include a unique population of patients whose disease is diagnosed for the first time and therefore the cellular and the genetic expression of inflammation will not be complicated by drug treatment, infection, or the trauma of surgery.